1. Medtech Insight
  2. >>Business
  3. >>R&D

TAVR Registry Data Shows Procedure Volume-Safety Relationship

 
• By Reed Miller

Data from 113,662 procedures at 555 hospitals from 2015 to 2017 shows an inverse relationship between the number of transfemoral transcatheter aortic valve replacement (TAVR) procedures a center or operator performs and the mortality rate for those patients. These results, published in The New England Journal of Medicine, lend support for CMS’ proposal to maintain center-volume requirements in the conditions for Medicare coverage for TAVR.

closeup pen in hand's doctor notes data on medical document. - Image
• Source: shutterstock.com

New data from the Society of Thoracic Surgeons/American College of Cardiology’s Transcatheter Valve Therapy (TVT) Registry show an inverse relationship between hospitals’ and operators' transcatheter aortic valve replacement (TAVR) procedure-volume and the mortality rate associated with those procedures.

The New England Journal of Medicine published the results of the retrospective study online April 3, a week after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More Haste Less Pace? Challenging The ‘Early As Possible’ Principle In Medtech Innovation

 
• By Stuart Grant

The rallying cry to start as early as possible has become increasingly common in the world of medical device development. Innovation expert Dr. Stuart Grant challenges this conventional wisdom, asking: Is "sooner" truly better, or is there a smarter path to market for your medical device?

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.

More from Business

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

 
• By Shubham Singh

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.